IE 11 is a very old Browser and it`s not supported on this site

16. Transactions with the Investment Manager and related party transactions

The asset management and administration of the Company has been delegated to Bellevue Asset Management AG. Based on the 1.1% p.a. all-in fee model, no additional costs incurred at Bellevue Asset Management AG were charged to the BB Biotech Group (2019: none). The amounts outstanding at the balance sheet date are disclosed in note 6, «Other short-term liabilities». 

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience.Use of cookies & disclaimer